Showing 7491-7500 of 8880 results for "".
- Makucell Unveils Renewnthttps://practicaldermatology.com/news/20120627-makucell_unveils_renewnt/2459779/Makucell, Inc., a pioneering regenerative biotechnology company, recently released the Renewnt (pronounced “Re-new-int”) brand. Renewnt's proprietary ingredient, Asymmtate, is a new approach to cellular aging, optimizing signals in the Wnt (pronounced “
- Wellness Center USA Inc. Signs Agreement to Acquire Psoria-Shield Inc.https://practicaldermatology.com/news/20120626-wellness_center_usa_inc_signs_agreement_to_acquire_psoria-shield_inc/2459782/Wellness Center USA Inc.(OTCQB/OTCBB: WCUI), a healthcare and nutraceutical company, signed a share exchange agreement to acquire Psoria-Shield Inc. (PSI), a developer and manufacturer of UV p
- Free Podcasts on Complete UV Protectionhttps://practicaldermatology.com/news/20120612-free_podcasts_on_complete_uv_protection/2459785/On the new edition of "Healthy Vision with Dr. Val Jones," dermatologist and author Jeanine Downie, MD, and Stephen Cohen, OD, past president of the Arizona Optometric Association, join Dr. Val to talk about the importance of sun protection. Both doctors share tips on steps adults and children can t
- OPTiM Trial for T-VEC in Unresectable Melanomahttps://practicaldermatology.com/news/20120604-optim_trial_for_t-vec_in_unresectable_melanoma/2459791/The OPTiM trial for T-VEC (formerly OncoVEXGM-CSF), an oncolytic HSV1 that selectively replicates in tumors, is now underway, according to a presentation by Kaufman, et al. at ASCO 2012. The randomized phase 3 trial will evaluate the efficacy and safety of talimogene laherparepvec (T-VEC) compared w
- Merz Realignment Focuses on Synergieshttps://practicaldermatology.com/news/20120518-merz_realignment_focuses_on_synergies/2459796/Merz is realigning and integrating its core businesses in the United States and Canada into one organization, with a single leadership team, the company announced. According to Merz, "the newly aligned structure is designed to stre
- Study: FDA Approves Drugs Faster than Europe, Canadahttps://practicaldermatology.com/news/20120517-study_fda_approves_drugs_faster_than_europe_canada/2459797/Drugs are approved faster in the US than in Europe and Canada, new research from Yale University School of Medicine shows. Authors of the study, published in The New England Journal of Medicine, reviewed decisions from 2001 to 2010 by the FDA and regulators in Canada and Europe, Health Canada and th
- Merz CEO Focused on Advancing the Companyhttps://practicaldermatology.com/news/20120515-merz_ceo_focused_on_advancing_the_company/2459801/William “Bill” Humphries, newly appointed CEO of Merz, Inc., has been setting the record straight. For example, addressing a recent injunction that bars the marketing of Xeomin for aesthetic indications, he insists, “the impact of the injunction isn
- FDA Extends Deadline for Sunscreen Label Compliancehttps://practicaldermatology.com/news/20120514-fda_extends_deadline_for_sunscreen_compliance/2459802/Sunscreen manufacturers have won a small victory from the Food and Drug Administration (FDA), which has extended the deadline for compliance with new labeling back to December 2013 for some companies. The industry pushed back on the agency, which ordered changes to sunscreens last summer with an ori
- La Roche-Posay Awards Two Researchershttps://practicaldermatology.com/news/20120514-la_roche-posay_awards_two_researchers/2459803/At its seventh annual North American Foundation Research Awards, La Roche-Posay honored winners Sarina B. Elmariah, MD, PhD and Marie S. Tuttle, MD. Both researchers received a $10,000 grant to continue dermatological research and were honored at t
- Provectus Pharmaceuticals' PV-10 Phase 2 Final Data To Be Presentedhttps://practicaldermatology.com/news/20120509-provectus_pharmaceuticals_pv-10_phase_2_final_data_to_be_presented/2459806/Phase 2 final data on PV-10 for metastatic melanoma by Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) will be presented at the second European PostASCO Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanom